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OBJECTIVE—We sought to determine whether exosome-like
vesicles (ELVs) released from adipose tissue play a role in
activation of macrophages and subsequent development of insu-
lin resistance in a mouse model.
RESEARCH DESIGN AND METHODS—ELVs released from
adipose tissue were puriﬁed by sucrose gradient centrifugation
and labeled with green ﬂuorescent dye and then intravenously
injected into B6 ob/ob mice (obese model) or B6 mice fed a
high-fat diet. The effects of injected ELVs on the activation of
macrophages were determined through analysis of activation
markers by ﬂuorescence-activated cell sorter and induction of
inﬂammatory cytokines using an ELISA. Glucose tolerance and
insulin tolerance were also evaluated. Similarly, B6 mice with
different gene knockouts including TLR2, TLR4, MyD88, and
Toll-interleukin-1 receptor (TIR) domain–containing adaptor
protein inducing interferon- (TRIF) were also used for testing
their responses to the injected ELVs.
RESULTS—ELVs are taken up by peripheral blood monocytes,
which then differentiate into activated macrophages with in-
creased secretion of tumor necrosis factor- (TNF-) and inter-
leukin-6 (IL-6). Injection of obELVs into wild-type C57BL/6 mice
results in the development of insulin resistance. When the
obELVs were intravenously injected into TLR4 knockout B6
mice, the levels of glucose intolerance and insulin resistance
were much lower. RBP4 is enriched in the obELVs. Bone
marrow–derived macrophages preincubated with recombinant
RBP4 led to attenuation of obELV-mediated induction of IL-6 and
TNF-.
CONCLUSIONS—ELVs released by adipose tissue can act as a
mode of communication between adipose tissues and macro-
phages. The obELV-mediated induction of TNF- and IL-6 in
macrophages and insulin resistance requires the TLR4/TRIF
pathway. Diabetes 58:2498–2505, 2009
A
dipose tissue macrophages (ATMs) inﬁltrate
adipose tissue during obesity and contribute to
the development of insulin resistance (1–5). In
both humans and rodents, accumulation of
ATMs in adipose tissue correlates with increasing body
weight and with increasing insulin resistance (6). ATMs are a
prominent source of proinﬂammatory cytokines, such as
tumor necrosis factor-(TNF-) and interleukin-6 (IL-6), that
can block insulin action in adipocytes, thus providing a
potential link between inﬂammation and insulin resistance
(7–12).
The events that lead to the initial activation of macro-
phages and their migration into adipose tissues are not
fully understood. Recent evidence suggests that inﬂamma-
tory processes induced by nutrient excess can cause
systemic insulin resistance via a mechanism involving
TLR4 (13–17). Peritoneal macrophages isolated from TLR4
knockout mice have a reduced capacity to produce cyto-
kines in response to lipid-induced activation of inﬂamma-
tion and insulin resistance (14). Moreover, TLR4 deletion
partly prevents diet-induced insulin resistance (17).
Several other pathways have been implicated in the
development of insulin resistance. Studies of mice and
humans have suggested that elevated levels of RBP4 in the
serum could play a causal role in insulin resistance.
Manipulation of the levels of RBP4 in the serum affects
insulin responses. In mice, transgenic overexpression of
RBP4 or injection of puriﬁed RBP4 protein into wild-type
C57BL/6 (B6) mice causes insulin resistance (18); con-
versely, RBP4 knockout mice exhibit enhanced insulin
sensitivity. In humans, the concentration of RBP4 in the
serum is elevated in insulin-resistant humans with obesity,
type 2 diabetes, and impaired glucose tolerance (18,19).
Moreover, the improvement in insulin sensitivity that
occurs in response to interventions such as gastric band-
ing surgery is associated with a lowering in the concen-
tration of RBP4 in the serum (18,20).
Exosomes are endosome-derived organelles (50–100
nm) that are actively secreted through an exocytosis
pathway. Recent studies have demonstrated that exo-
somes can mediate intercellular cross-talk under normal
and pathological conditions (21,22). Although communica-
tion between adipose tissue and immune cells appears to
be of importance in the interconnection between obesity
and inﬂammation and the development of diabetes, re-
search into the signals underlying this communication has,
for the most part, been limited to analysis of the roles of
cytokines and chemokines. The possibility that adipose
tissue–derived exosome-like vesicles (ELVs) are involved
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cation has not been explored to any great extent.
In the present study, we found that obELVs are released
from adipose tissue, are preferentially taken up by periph-
eral blood monocytes, and stimulate the differentiation of
the monocytes into activated macrophages. This ﬁnding
suggests that the obELVs released by the adipose tissue
could act as a mode of communication between adipose
tissues and macrophages. Evidence that this interaction
contributes to the development of insulin resistance was
obtained by administering obELVs into wild-type B6 mice
and the induction of the insulin-resistant phenotype in a
mouse model.
RESEARCH DESIGN AND METHODS
C57BL/6j (B6) male mice (Jackson Laboratory) were maintained on a high-fat
diet (HFD) (60% fat, LabDiet, 5001; Richmond, IN) or a standard rat diet (10%
fat) for 3 months starting at 2 months of age. Male B6 ob/ob mice, B6.Cg-
Nfkb1
tm1Bal/J, and control littermates were purchased from Jackson Labora-
tories. TLR2, TLR4, MyD88, and Toll-interleukin-1 receptor (TIR) domain–
containing adaptor protein inducing interferon- (TRIF) knockout male mice
on a B6 background were provided by Dr. Shizuo Akira (University of Osaka,
Japan). All of the animal experiments were performed under protocols
approved by the University of Alabama at Birmingham.
ELV preparation and electron microscopy examination. To isolate the
ELVs, visceral adipose tissue of 5-month-old mice was washed with PBS and
cut into small pieces 4 mm, transferred to six-well plates containing 3
ml/well of Dulbecco’s modiﬁed Eagles medium (Invitrogen) supplemented
with 50 g/ml gentamicin and 10% FBS with bovine sera exosomes prede-
pleted using a method as described previously (23), and cultured in a 37°C
incubator in an atmosphere of 5% CO2/95% air. The cultured supernatants
were used for ELV puriﬁcation, which was accomplished by differential
centrifugation using a previously described method (24). Concentrated ELVs
were analyzed using a Hitachi H7000 electron microscope (Electronic Instru-
ments) as previously described (24). Thymus exosomes were isolated from
male B6 mice using a method as described previously (25).
Labeling macrophages with ﬂuorescent dyes and macrophage trafﬁck-
ing in vivo. PKH67 and PKH26 kits were used for labeling bone marrow–
derived macrophages (BMDM) according to the manufacturer’s instructions
(Sigma). BMDMs from 7-day primary cultures of femoral bone marrow from 6-
to 8-week-old female wild-type mice were generated as described previously
(26) and detailed in the supplemental Methods in the online appendix
available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-0216/
DC1. The trafﬁcking of injected macrophages was monitored by ﬂuorescence-
activated cell sorter (FACS) analysis of labeled macrophages in adipose
tissue, liver, spleen, and bone marrow. As a means to monitor the proliferation
potential of injected macrophages, 24 h before mice were killed, 1 mg of
bromodeoxyuridine (BrdU; Sigma), dissolved in 300 l PBS, was injected
intraperitoneally with a second dose 3 h before the mice were killed. The
leukocytes were then isolated from each tissue including adipose, liver,
spleen, and bone marrow using protocols as described previously (24) and
stained with anti-BrdU antibody. Once stained, the leukocytes were analyzed
by FACS using a protocol described previously (27).
Glucose tolerance and insulin tolerance test. Mice were injected intrave-
nously with ELVs (30 g/mouse) every 3 days for 21 days. After the last
injection, glucose tolerance and insulin tolerance tests were performed using
a method as described (7) and detailed in the supplemental Methods.
Glucose uptake assay. C2C12 myocytes were purchased from American
Type Culture Collection and cultured in -minimal essential medium supple-
mented with 10% FBS. Once 80% conﬂuency was attained, the C2C12 myocyte
culture medium was replaced with conditioned media from bone marrow
precursor cells that had been pretreated with wild-type (wt)ELVs or obELVs
or thymus exosomes (10 g/ml) for 14 days in the presence of granulocyte
monocyte colony–stimulating factor (GM-CSF; 20 ng/ml). The effects of
combined medium with or without addition of anti–TNF- and anti–IL-6
antibodies on the [
3H]glucose uptake of C2C12 myocytes was assessed as
described (28) and detailed in the supplemental Methods.
Macrophages treated with a recombinant mouse RBP4. A recombinant
mouse RBP4 (R&D Systems, catalog number 3476-LC) was purchased and
used for stimulating BMDMs (1  10
5/100 l in RPMI160 medium). Twenty-
four hours after the stimulation, the cell culture supernatants were harvested
and assayed for TNF- and IL-6 using an ELISA. To determine the in vivo
effects of a mouse RBP4 on the induction of IL-6 and TNF-, wild-type B6 mice
or TLR4 knockout B6 mice were injected intravenously with mouse RBP4 (250
g/mouse in 200 l of PBS). Six hours after the injection, serum levels of IL-6
and TNF- were measured using a standard ELISA. To determine whether the
cells pretreated with recombinant mouse RBP4 respond to subsequent ELV
RBP4 stimulation, the BMDMs treated with mouse RBP4 were washed with
PBS 3 times and then cultured in the presence of wtELVs or obELVs (10
g/ml) for an additional 24 h. TNF- and IL-6 in the supernatants was
quantiﬁed using an ELISA. The details of other methods used for this study
have been published by this laboratory and are described in the supplemental
Methods.
Statistical analysis. Statistical differences between groups were determined
by ANOVA with multiple comparisons using Fischer’s post hoc analysis. The
Student’s t test was used for comparisons when only two parameters were
evaluated. P values  0.05 were considered signiﬁcant.
RESULTS
ELVs released from adipose tissue. Others have dem-
onstrated previously that exosomes are released by 3T3-
L1, a precursor adipocyte cell line (29,30). We found that
more ELVs are released in 30-min ex vivo adipose tissue
cultures of age-matched wild-type (B6) mice fed a HFD
over 3 months (HFDELVs, 16.5  1.2 g/g of adipose
weight) and of leptin-deﬁcient (ob/ob) B6 mice (obELVs,
14.4  1.1 g/g of adipose weight) when compared to
adipose tissue cultures of wild-type lean B6 mice (wtELVs,
4.1  1.0 g/g of adipose weight). The quantity of ELVs
released from adipose tissue increased over a period from
3 0m i nt o6ho fe xvivo adipose tissue culture (supple-
mental Fig. S1A), that is, 16.5–22.2 g/g HFDELVs; 14.4–
23.2 g/g obELVs; and 4.1–6.7 g/g wtELVs. Electron
microscopy examination revealed vesicles that measured
60–100 nm in diameter and had a cup-shaped morphol-
ogy (supplemental Fig. S1B). Neither calnexin nor Lamp-1
were detectable when the ELVs were analyzed by immu-
noblotting (supplemental Fig. S1C), indicating that our
ELV preparations were free of contaminating nonexosome
membrane proteins (31). Further evidence that the vesi-
cles were exosomes was obtained through analysis of the
protein composition using linear ion trap mass spectrom-
etery (LTQ LC/MS) (supplemental Table S1). These analy-
ses indicated a protein composition typical of exosomes
derived from other cell types (32–35) (supplemental Table
S2). Speciﬁc proteins were at undetectable levels in wt-
ELVs when compared with protein detected in obELVs
and HFDELVs (supplemental Table S1), but in both cases
the ELVs contained proteins known to be involved in cell
metabolism, membrane trafﬁcking, multiple small GTP-
binding proteins, integral membrane proteins, and several
class E vacuolar protein sorting proteins. The fatty acid
composition of the obELVs was almost exclusively
palmitic acid (n  8, 40.22  3.82%) and stearic acid
(52.71  4.42%) (supplemental Table S3). Because there
are minor differences in the protein composition of ELVs
released from B6 mice fed an HFD in comparison with
obELVs (supplemental Table S1), we focused on the B6
obELVs released from adipose tissues at 30-min ex vivo
culture for the remainder of study because a larger amount
of adipose tissue for isolation of ELVs was available from
ob/ob mice of the same age.
ELVs released from the adipose tissue of ob/ob mice
activate monocytes. We determine whether obELVs re-
leased from adipose tissue are taken up by cells of the
immune system. We labeled obELVs with PKH67 dye
before injecting them intravenously into B6 mice fed an
HFD or standard diet for 3 months starting at 2 months of
age. FACS analysis of single-cell suspensions of several
tissues that had been harvested 24 h after the injection of
obELVs indicated that more than 1.1% of total blood cells
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80% of the cells having taken up obELVs were CD11bF4/
80
	 monocytes (supplemental Fig. S2A and B), but no B
cells, T cells, nor natural killer cells had taken up obELVs
(data not shown). This result is unlikely because of PKH67
dye leakage from obELVs to the monocytes as no PKH67-
positive macrophages were detected in the tissues of mice
having been injected intravenously with free PKH67 dye
(data not shown). FACS analysis of the gated PKH67
	
cells isolated from peripheral blood further indicated that
the monocytes (CD11b
	F4/80
	PKH67
	) that had taken up
the obELVs expressed higher levels of the monocyte
receptors ICAM-1 (intracellular adhesion molecule-1),
CD204, and MHCII (major histocompatibility complex II)
than did monocytes that had taken up ELVs isolated from
lean, wild-type B6 mice (wtELVs) (Fig. 1A), although both
wtELVs and obELVs were taken up by the monocytes with
equal efﬁciency (data not shown). In addition, at days 1
and 7 after injection of the ELVs there were higher levels
of the proinﬂammatory cytokines IL-6 and TNF- in the
sera of the mice that had been injected with obELVs than
in the sera of B6 mice that had been injected with wtELVs
(Fig. 1B). Analysis of ELISA results indicated that the
injection of ELVs does not induce the host to generate
antibodies against the injected ELVs (data not shown),
implying that induction of inﬂammatory cytokines may not
lead to further activation of adaptive immune responses.
The experiments as described above were also repeated
in B6 mice fed a standard rat diet, and similar results
were obtained (data not shown), suggesting that HFD
preconditioning is not required for obELV-mediated
activation of monocytes.
ObELV-mediated activation of macrophages impairs
glucose uptake and the insulin response of myocytes
in vitro. To determine whether the obELV-activated mac-
rophages produce factors that affect insulin sensitivity, we
determined the effect of conditioned medium harvested
from bone marrow precursor cells that had been pre-
treated with obELVs for 14 days on glucose uptake and the
insulin response of myocytes. The conditioned medium
was harvested from 14-day cultures of bone marrow cells
that had been pretreated with obELVs or wtELVs and
cultured in the presence or absence of GM-CSF. In the
course of these experiments, we noted that on day 4 after
the addition of the ELVs to the day 0 cultured bone
marrow precursor cells that the bone marrow precursors
exhibited differentiation into macrophages instead of den-
dritic cells and that the differentiation into macrophages
occurred when the dendritic cell differentiation factor
GM-CSF had been added to the day 0 cultures (supplemen-
tal Fig. S3A). This differentiation did not occur when
wtELVs (supplemental Fig. S3A) or thymus exosomes
(supplemental Fig. S3D) were added to the day 0 bone
marrow precursor cultures. These obELV-stimulated mac-
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FIG. 1. Adipose obELVs activate macrophages. A: Wild-type B6 mice fed an HFD for 3 months starting at 2 months of age were injected
intravenously with the PKH67
-labeled obELVs or wtELVs (30 g/mouse). Twenty-four hours after the injection, CD11b
F4/80
PKH67
 cells
from peripheral blood were analyzed for the presence of CD204, ICAM-1, and MHCII markers. Results were pooled from ﬁve independent
experiments (n  5 mice/experiment) and are presented as the means  SE, *P < 0.05, **P < 0.01. B: Mice treated as described above at day 1
and 7, peripheral blood was collected at 4 h after the ELV injections, and the serum concentration of IL-6 and TNF- were determined using a
standard ELISA, *P < 0.05, **P < 0.01 (n  5 mice per group). i.v., intravenous.
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tal Fig. S3B), even in the absence of growth factors. These
activated macrophages secreted higher quantities of mac-
rophage colony-stimulating factor, IL-6, and TNF- into
the culture supernatants than did the bone marrow pre-
cursors that had been stimulated with wtELVs (supple-
mental Fig. S3C) or thymus exosomes (supplemental Fig.
S3E). Furthermore, elevated obELV concentrations were
associated with the promotion of bone marrow precursor
differentiation (supplemental Fig. S4A), proliferation (sup-
plemental Fig. S4B), and induction of IL-6 (supplemental
Fig. S4C).
Upon addition of the conditioned medium to the myo-
cyte cultures, the levels of phosphorylation of Akt were
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FIG. 2. Adipose obELVs promote the differentiation and proliferation of BMDMs and impair activation of the insulin signaling pathway in vitro
and macrophage inﬁltration into adipose tissues in vivo. C2C12 cells at 80% conﬂuency were cultured for 24 h in the presence of conditioned
medium harvested from 14-day cultures of bone marrow cells that had been pretreated with obELVs, wtELVs, or thymus exosomes (10 g/ml) at
day 0 of the culture and cultured in the presence or absence of GM-CSF. After a 3-h starvation, the C2C12 cells were stimulated with insulin (100
nmol/l) for 20 min and either lysed for Western blot analysis of phosphorylated Akt (A) or used for glucose uptake testing (B). Results presented
are representative of a minimum of three experiments (A) or data are the means  SE of three experiments with two replicates of each (B). *P
< 0.05; **P < 0.01. C: B6 mice fed an HFD were intravenously injected with a mixture (1:1) of 4  10
6 of BMDMs
PKH26 that had been preincubated
with obELVs with BMDMs
PKH67 that had been preincubated with wtELVs. The percentage of injected macrophages inﬁltrating adipose tissue,
liver, spleen, and bone marrow were determined by FACS analysis of PKH67 and PKH26 14 days after the injection. D: The PKH67
 or PKH26

cells were gated and analyzed for CD11b
F4/80
. The proliferation of injected ﬂuorescent dye–labeled CD11b
F4/80
 macrophages was then
determined by FACS analysis of BrdU
 cells in the adipose tissue, liver, spleen, and bone marrow. A representative graph of FACS analysis of
macrophage inﬁltration in adipose tissue is shown and the data represent the means  SE from ﬁve mice from each group. **P < 0.01. BM, bone
marrow.
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medium harvested from macrophages pretreated with
obELVs than in the myocytes cultured with conditioned
medium from wtELVs (Fig. 2A). Furthermore, basal and
insulin-stimulated transport of glucose was inhibited in
myocytes treated with obELV-conditioned medium, indi-
cating that insulin function is also impaired (Fig. 2B). The
conditioned medium–induced impairment of insulin re-
sponses was not observed when bone marrow precursors
were stimulated with thymus exosomes (Fig. 2B), suggest-
ing that obELV-mediated impairment of insulin responses
in myocytes is adipose tissue exosome speciﬁc.
In addition, in agreement with the data published by
other groups (36–38), addition of anti–TNF- and anti–IL-6
neutralizing antibodies to the conditioned medium har-
vested from the obELV-treated wild-type bone marrow
precursor cells led to a partial reversal of the impaired
responses (supplemental Fig. S5).
To assess the homing of the macrophages that had taken
up the ELVs, we injected B6 mice fed an HFD over 3 months
with a mixture of PKH26-labeled BMDMs that had been
preincubated with obELVs (BMDMs
PKH26	) with PKH67-
labeled BMDMs that had been preincubated with wtELVs
(BMDMs
PKH67	). FACS analysis of the tissues harvested 14
days after the BMDMs
PKH26	 or BMDMs
PKH67	 injections
revealed that the number of PKH26
	 macrophages were
remarkably higher in adipose tissue and liver but not in the
spleen and bone marrow (Fig. 2C). Analysis of the prolifer-
ation of the inﬁltrating macrophages (CD11b
	F4/
80
	PKH26
	) using a BrdU incorporation assay suggested
that the macrophages that had been pretreated with obELVs
proliferated faster than those pretreated with wtELVs (Fig.
2D). Preferential homing to and faster proliferation of mac-
rophages prepulsed with obELVs, but not wtELVs, in adipose
and liver tissue was also observed in the same-aged B6 ob/ob
mice (data not shown).
ObELV-induced activation of macrophages is depen-
dent on the TLR4 pathway. The TLR pathway has been
shown to play a role in the development of obesity (14);
therefore, we repeated the above studies using BMDMs
from TLR2 knockout, TLR4 knockout, and B6 wild-type
mice. ELISA analysis of supernatants obtained from the
obELV-stimulated BMDMs show there were much higher
levels of IL-6 and TNF- in the culture medium of the
obELV-treated BMDMs from TLR2 knockout and wild-type
B6 mice than the obELV-treated BMDMs from TLR4
knockout mice (Fig. 3A). FACS analysis of the cells
indicated that the obELV-induced expression of CD204
was also lower in the obELV-treated BMDMs from the
TLR4 knockout mice than the obELV-treated BMDMs from
the wild-type B6 mice and the TLR2 knockout mice
(supplemental Fig. S6). Similar results were obtained
when ICAM and MHCII expression were analyzed by FACS
(data not shown). Together, these data suggest that
obELVs are capable of utilizing TLR4 signaling to induce a
macrophage inﬂammatory response. To further substanti-
ate the involvement of the TLR4 signaling pathway, we
sought to determine if knockout of either MyD88 or TRIF
affected the response, as both these molecules can be used
as adaptors for the TLR4 signaling pathway (39–42).
Knockout of TRIF, but not MyD88, substantially inhibited
the obELV-mediated induction of IL-6 and TNF- (Fig. 3B),
suggesting that this response is TRIF dependent.
In addition, the combined medium harvested at 24 h
after addition of obELV (10 g/ml) to BMDMs from TLR4
knockout B6 mice led to better glucose uptake or
insulin response of myocytes than from wild-type B6
mice (Fig. 3C).
ObELV RBP4 plays a role in the adipose obELV-
mediated, TLR4-dependent induction of macrophage
IL-6 and TNF-. RBP4 knockout mice display enhanced
insulin sensitivity (18). We found that RBP4 is present in
ELVs isolated from the adipose tissue of B6 ob/ob mice and
in signiﬁcantly higher amounts than wtELVs (Fig. 4A)
isolated from age-matched mice. The addition of recombi-
nant RBP4 (rRBP4) alone to BMDMs from wild-type B6
mice induced the production of IL-6 and TNF- in a
concentration-dependent manner (supplemental Fig. S7A).
This RBP4-induced production of IL-6 and TNF- was
dependent on TLR4 because there was less induction of
either cytokine when TLR4 knockout macrophages were
used in experiments (Fig. 4B). This result was also sup-
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injection of recombinant RBP4 (250 g/mouse) in TLR4
knockout B6 mice, a reduced induction of serum TNF-
and IL-6 had occurred (supplemental Fig. S7B). Nuclear
factor (NF)-
B activation has been shown to play a role in
TLR4-driven inﬂammatory responses. This RBP4-induced
production of IL-6 and TNF- was also attenuated when
BMDMs from NF-
B p50 knockout mice were used (sup-
plemental Fig. S7C). Collectively, these data suggest that
RBP4-mediated induction of TNF- and IL-6 is regulated
through TLR4/NF-
B pathway.
To address the possibility that ELV RBP4 utilizes a
different pathway to stimulate TNF- and IL-6 production
by BMDMs than does free RBP4, we used a competitive
assay. The BMDMs were pretreated 24 h before the
addition of obELVs with mouse RBP4 or its dialyzed buffer
as a control. ELISA analysis of the supernatants conﬁrmed
that obELVs or RBP4 alone could induce the production of
TNF- and IL-6; however, pretreatment of the BMDMs
with RBP4 attenuated the ability of the adipose obELVs to
induce the production of TNF- and IL-6 (Fig. 4C), sug-
gesting that RBP4 may compete with the same pathway as
obELVs to induce TNF- and IL-6.
ELVs from the adipose tissue of ob/ob mice induce
insulin resistance in mice. To test the effects of ELVs in
vivo, B6 and TLR4 knockout mice were injected intrave-
nously (30 g/mouse) every 3 days for 3 weeks with ELVs
released from the adipose tissue of lean wild-type mice or
ob/ob mice. Glucose uptake, insulin response, and serum
levels of TNF- and IL-6 were determined after the last
injection. Remarkably, the injection of ELVs released from
the adipose tissue of ob/ob mice, but not wild-type mice, led
to the development of glucose intolerance (Fig. 5A) and
insulin resistance in wild-type mice (Fig. 5B). Moreover,
the levels of glucose intolerance (Fig. 5A), insulin resis-
tance (Fig. 5B), and serum TNF- and IL-6 (Fig. 5C) were
much lower in the TLR4 knockout mice that were treated
with the obELVs than the wtELVs. Thus, ELVs released
from the adipose tissue of ob/ob mice substantially en-
hance the development of insulin resistance and impair
glucose tolerance and induction of inﬂammatory cytokines
in a TLR4-dependent manner.
DISCUSSION
In this study, we found that ELVs released from adipose
tissue of ob/ob mice induce macrophage activation in a
TLR4-dependent manner and that the RBP4 that is incor-
porated in these ELVs plays a role in the induction of
macrophage activation. Several independent lines of evi-
dence support these conclusions. The exposure of wild-
type macrophages to obELVs resulted in an increased
production of the proinﬂammatory cytokines IL-6 and
TNF-, enhanced the migration of macrophages into adi-
pose tissue and the liver, and promoted the development
of insulin resistance. In contrast, the intravenous injection
of obELVs into TLR4 knockout mice did not result in the
development of insulin resistance, and treatment of TLR4
knockout macrophages with obELVs did not enhance the
production of IL-6 or TNF-. Adipose obELV RBP4 protein
can induce the production of macrophage IL-6 and TNF-
in a TLR4-dependent manner.
Using an ex vivo adipose tissue culture approach, we
provide evidence that ELVs are secreted from adipose
tissue. Unlike the data for the exosomes released from in
vitro cultured cells, the data generated using the exosomes
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are more relevant to what may take place in an in vivo
obesity mouse model. The released exosomes are pre-
dicted to have both local and systemic effects. The exo-
somes could be taken up by resident macrophages leading
to their activation in adipose tissue. Because of resident
macrophage activation, more monocytes/macrophages
may be recruited into adipose tissue to further augmented
inﬂammatory responses with more ELVs released from
adipose tissue as the size of adipocytes increased. This
increase in adipose cell size is one of the major features of
obesity and may contribute to an increased amount of
ELVs circulating in the peripheral blood. Therefore, acti-
vated monocytes circulating in the peripheral blood could
be further expanded by these ELVs circulated in the
peripheral blood.
Although the factors driving monocytes/macrophages to
preferentially inﬁltrate adipose tissue and liver are not
clear, this study provides strong evidence supporting the
idea that the macrophage TLR4-mediated pathway plays a
role in obELV-mediated activation of macrophages. A
physiological role of TLR4 in insulin resistance was dem-
onstrated previously in a model in which TLR4 knockout
mice were fed an HFD (13,14,17). We found that the
obELV-mediated induction of IL-6 and TNF- occurs
through activation of the TLR4 pathway of macrophages.
Our data further suggest that the exosome-mediated in-
duction of IL-6 and TNF- of macrophages is dependent on
the TLR4/TRIF pathway. This is consistent with recent
data suggesting that signaling through the TRIF-mediated
pathway can activate NF-
B leading to the production of
IL-6 and TNF- (40,42–44). The preferential signaling
through the TLR4/TRIF pathway rather than the TLR4/
MyD88 pathway is of particular interest with respect to the
potential mechanisms by which the obELVs may act to
stimulate the macrophages. It has been reported that the
TLR4-TRIF pathway is activated in endosomes, whereas
the TLR4-MyD88 pathway is activated at the plasma mem-
brane level (41,45). The biogenesis of exosomes is consid-
ered to be initiated in endosomes, and it is conceivable
that the proteins contained in exosomes may preferen-
tially home to the endosome compartment of the cells
where they are taken up and that this may inﬂuence the
effects of the exosomes on the cells in terms of the type of
response they elicit and the magnitude of the response.
Currently, it is unknown whether the activation of the
TLR4/TRIF pathway and the induction of IL-6 and TNF-
by obELVs is dependent on obELV RBP4. A neutralizing
anti-RBP4 antibody to block obELV RBP4–mediated in-
duction of IL-6 and TNF- would further conﬁrm the
results presented in Fig. 4C. We have been unable to
develop a satisfactory neutralizing anti-RBP4 antibody,
and there is no commercially available anti-RBP4 antibody
for use in neutralization experiments at the present time.
Finally, we propose a hypothetical model in which
obesity may cause dysregulation of the adipose exosome
protein and/or fatty acid sorting machinery, resulting in
the unregulated sorting of certain proteins/lipids into
exosomes. Factors, such as inﬂammatory cytokines that
are high-risk indicators for developing obesity and insulin
resistance, may play a direct role in dysregulation of the
cell sorting machinery. Because of the dysregulation, the
exosomes released by the adipose tissue in obese mice
contain proinﬂammatory favorable proteins. These exo-
somes are capable of a potent stimulatory effect locally
and at some distance from the adipose tissue, which could
mediate both the obesity-associated inﬂammatory re-
sponses and the development of insulin resistance. We
propose that the contribution of adipose ELVs to obesity-
associated insulin resistance is likely multifactorial. It is
conceivable that if a single protein could be responsible
for certain biological effects without regulating other
effects, the formation of exosomes as a complex to exe-
cute their immune regulatory function would seem to
waste host energy to assemble.
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